Fundraising Fox
/Companies
Sign in

Hancock Jaffe Laboratories

NASDAQ: NVNO

Irvine, US · Delaware corporation

Find your way into Hancock Jaffe Laboratories

Sign up to see every warm intro you have to Hancock Jaffe Laboratories

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Hancock Jaffe Laboratories team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

enVVeno Medical Corporation develops tissue-based replacement venous valves to treat chronic venous insufficiency in the deep venous system of the leg. The company is pursuing FDA approval for its next-generation enVVe System, a minimally invasive, catheter-based replacement valve designed for patients with severe chronic venous disease.

Biotech

Founders & leadership

SM
Susan MontoyaExecutive
RA
Robert A. BermanDirector, Chief Executive Officer
JB
Jennifer BrightChief Financial Officer
HA
Hamed AlaviSenior Vice President and Chief Technology Officer
MHMarc H. Glickman
Marc H. GlickmanSenior Vice President and Chief Medical Officer
NJ
Norman JaffeNamed on SEC filing

Board

YZ
Yuri ZhiviloBoard director

Reported raises · per SEC filings

Form D private placements

$6.8M disclosed across 6 rounds · 2015–2020

▶$1.6MraisedAug 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Francis DuhayDirector
  • Robert Andrew BermanExecutive Officer, Director
  • Robert C. GrayDirector
  • Mark H. GlickmanExecutive Officer
  • Sanjay ShrivastavaDirector
  • Craig GlynnExecutive Officer
  • Matthew M. JenusaitisDirector
Offering amount
$1.6M
Amount sold
$1.6M
Minimum investment
$100K
Sales commissions
$102.8K
Placement agents
Ladenburg Thalmann & Co. Inc.,
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$650KraisedMar 2020 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert A. BermanExecutive Officer, Director
  • Robert C. GrayDirector
  • Sanjay ShrivastavaDirector
  • Francis Duhay, M.D.Director
  • Marc H. Glickman, M.D.Executive Officer
  • Robert RankinExecutive Officer
  • Matthew M. JenusaitisDirector
Offering amount
$890K
Amount sold
$650K
Sales commissions
$65K
Placement agents
Spartan Capital Securities LLC
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedMay 2019 · 105 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sanjay ShrivastavaDirector
  • Marc H. Glickman, M.D.Executive Officer
  • Yury ZhiviloExecutive Officer, Director
  • Robert A. BermanExecutive Officer, Director
  • Francis DuhayDirector
  • Robert RankinExecutive Officer
Offering amount
$2.7M
Amount sold
$2.7M
Sales commissions
$297.4K
Placement agents
NETWORK 1 FINANCIAL SECURITIES, INC.
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJun 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benedict Broennimann, MDExecutive Officer
  • Gennady AlferenkoDirector
  • Marc Glickman, MDExecutive Officer, Director
  • Susan MontoyaExecutive Officer
  • Yury ZhiviloDirector
  • William AbbottExecutive Officer
  • Robert AndersonDirector
  • Robert DoyleDirector
Offering amount
$2M
Amount sold
$1M
Sales commissions
$100K
Placement agents
Alexander Capital, L.P.
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$194KraisedMar 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert DoyleDirector
  • Gennady AlferenkoDirector
  • Yury ZhiviloDirector
  • Benedict Broennimann, MDExecutive Officer
  • Susan MontoyaExecutive Officer
  • William AbbottExecutive Officer
  • Robert AndersonDirector
  • Marc Glickman, MDExecutive Officer, Director
Offering amount
$7.5M
Amount sold
$194K
Sales commissions
$937.5K
Placement agents
Newbridge Securities Corporation
First sale
Mar 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$680KraisedDec 2015 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Norman JaffeExecutive Officer, Director
  • Susan MontoyaExecutive Officer, Director
  • Yuri ZhiviloDirector
Offering amount
$6.5M
Amount sold
$680K
Minimum investment
$50K
Sales commissions
$650K
Placement agents
Legend Securities, Inc.
First sale
Dec 2015
Incorporated
Corporation, New York
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Hancock Jaffe Laboratories do?
enVVeno Medical Corporation develops tissue-based replacement venous valves to treat chronic venous insufficiency in the deep venous system of the leg. The company is pursuing FDA approval for its next-generation enVVe System, a minimally invasive, catheter-based replacement valve designed for patients with severe chronic venous disease.
How much funding has Hancock Jaffe Laboratories raised?
Hancock Jaffe Laboratories has disclosed $6.8M raised across 6 rounds.
Where is Hancock Jaffe Laboratories headquartered?
Hancock Jaffe Laboratories is headquartered in Irvine, US.